Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.
What happened
FDA reviewed records Ningbo Riway submitted after a March 11, 2024 records request, not an inspection. FDA found Current Good Manufacturing Practice (CGMP) failures: no identity testing of incoming components including isopropyl alcohol for methanol, no adequate finished-product testing including microbiological tests for products labeled sterile, and inadequate quality-unit oversight of the water system and component approvals. FDA also found KLEAN FREAK BODY WIPE and JJ CARE ADHESIVE REMOVER WIPES were unapproved new drugs and misbranded based on their labels; the firm was placed on Import Alert 66-40, which can block U.S. entries, on November 7, 2024.
What FDA found
The firm did not test each incoming component lot for identity and did not verify supplier test results at appropriate intervals; it also did not test isopropyl alcohol for methanol.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not adequately test finished drug products before release for active ingredient identity and strength, impurities, and microbiological quality, including for products labeled sterile.
21 CFR 211.165(a)The quality unit did not adequately oversee quality, including the water system used for sterile IPA prep pads and approval or rejection of components.
21 CFR 211.22(a)KLEAN FREAK BODY WIPE is an unapproved new drug (sold without required FDA approval or OTC rule compliance) and misbranded (illegally labeled) because its label directions extend use beyond the hands allowed for consumer antiseptic rubs.
FD&C Act sections 505(a), 301(d), and 502(ee); section 505GJJ CARE ADHESIVE REMOVER WIPES is an unapproved new drug and misbranded because its 1% isopropyl alcohol is below the required concentration for an OTC antiseptic.
FD&C Act sections 505(a), 301(d), and 502(ee); section 505G and OTC Monograph M003
What FDA wants
FDA tells the firm to correct the violations promptly, engage a qualified CGMP consultant if it intends to resume making drugs for the U.S. market, and respond in writing within 15 working days with corrective actions and a plan to prevent recurrence. If it cannot finish, it must give reasons and a completion schedule.
Who should pay attention
- brands that buy OTC wipes or prep pads from this contract manufacturer
- U.S. distributors and importers of antiseptic wipes
- companies relying on supplier COAs for high-risk ingredients
This is a summary. Read the original letter on fda.gov.